Autoimmune Disease Diagnostics Market - Products, Disease Types and Test Types

Advances in genomics, proteomics, bioinformatics, and artificial intelligence are transforming the field, enabling more precise, personalized, and predictive diagnostic solutions that enhance clinical decision-making.

The global autoimmune disease diagnostics market is estimated at USD 6.2 billion in 2025 and projected to reach USD 10.2 billion by 2032, registering a CAGR of 7.4% during 2025 to 2032. Growth is driven by the rising prevalence of over 100 autoimmune disorders, including lupus, multiple sclerosis, and rheumatoid arthritis, alongside lifestyle and environmental factors that elevate risk. Growing awareness, government initiatives, and supportive reimbursement policies in developed economies are encouraging early testing. Rapid progress in immunoassays, biomarker research, molecular diagnostics, and next-generation sequencing has improved diagnostic speed and accuracy, while AI-enabled analytics enhance data interpretation. The expansion of point-of-care and at-home testing, supported by microfluidics-based platforms, is improving accessibility across regions. Strengthened healthcare infrastructure in Asia-Pacific, rising global health expenditure, and strategic collaborations between pharmaceutical and diagnostic firms are accelerating innovation. With aging populations, preventive healthcare trends, and the shift toward precision medicine, autoimmune disease diagnostics are becoming central to next-generation healthcare delivery.

Autoimmune Disease Diagnostics Regional Market Analysis

North America accounts for the largest share of the global autoimmune disease diagnostics market, estimated at 41% in 2025, supported by a high disease burden, advanced healthcare systems, favorable reimbursement policies, and strong presence of leading diagnostic companies. The United States anchors this leadership with extensive adoption of ELISA, chemiluminescence, and AI-based diagnostic platforms, complemented by robust R&D investments and broad insurance coverage. In contrast, Asia-Pacific is set to expand the fastest, recording a CAGR of 8.7% from 2025 to 2032, driven by rising prevalence of autoimmune conditions, improved healthcare access, and government-supported screening initiatives. China leads the region with its vast patient base and large-scale diagnostic programs, while India emerges as the fastest-growing market owing to expanding infrastructure, affordable test kits, and greater disease awareness. Japan continues to play a pivotal role in precision diagnostics, particularly for thyroid and celiac disorders, supported by national health programs and its aging population. The region's growth is reinforced by domestic manufacturing incentives, international partnerships, and increasing investments in healthcare innovation.

Autoimmune Disease Diagnostics Market Analysis by Product

Reagents & consumables represent the largest product category in the autoimmune disease diagnostics market, holding 68% of the share in 2025, owing to their recurring demand in high-volume laboratory testing and the increasing use of advanced assay kits for rapid, reliable results. Their continuous consumption in ELISA, immunofluorescence, and multiplex immunoassays, requiring specialized reagents, antibodies, and buffers, sustains this dominance. Expanding diagnostic networks, from hospitals to independent labs, further amplifies demand, while innovations in biomarkers and assay design drive the need for customized, high-precision reagents. Meanwhile, instruments, though smaller in share, are expected to post the fastest growth exceeding 8% CAGR during 2025-2032, driven by technological progress in lab automation, multiplex platforms, and AI-integrated systems enabling high-throughput, accurate, and rapid testing. The growing focus on early detection and automation supports steady instrument adoption, despite higher initial costs and longer replacement cycles.

Autoimmune Disease Diagnostics Market Analysis by Disease Type

Systemic autoimmune diseases lead the market in 2025 with a 63% share and are projected to grow at the fastest CAGR of 7.6% through 2032. Their dominance is attributed to the complexity of multi-organ conditions like rheumatoid arthritis, lupus, and multiple sclerosis that require comprehensive antibody panels and frequent monitoring. Rheumatoid arthritis holds the largest portion within this group at 36.7% in 2025, reflecting its widespread prevalence and the need for early biomarker-based detection through RF and anti-CCP assays. Multiple sclerosis, on the other hand, is emerging as the fastest-growing condition with a 8.3% CAGR, fueled by expanding biomarker research and the emphasis on early intervention to manage progression.

Autoimmune Disease Diagnostics Market Analysis by Test Type

Among test types, Antinuclear Antibody (ANA) tests hold the leading share of 31% in 2025, reflecting their central role in early detection and ongoing monitoring of autoimmune conditions. Their extensive use in hospitals and diagnostic laboratories is reinforced by continuous improvements in ELISA, indirect immunofluorescence, and multiplex assay technologies that enhance accuracy and throughput. Growing disease awareness, expansion of diagnostic facilities, and rising healthcare investment further sustain this segment's strong position. Meanwhile, Autoantibodies & Immunologic Tests are set to record the fastest growth, at 7.8% CAGR between 2025 and 2032, driven by their precision in detecting early-stage autoantibodies, the adoption of multiplexed and AI-assisted platforms, and increasing use in personalized medicine. The need for accurate, rapid, and cost-effective diagnostic solutions continues to fuel robust growth across both ANA and autoantibody testing segments worldwide.

Autoimmune Disease Diagnostics Market Report Scope

This global report on Autoimmune Disease Diagnostics analyzes the market based on product, disease type, and test type. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.

Key Metrics

• Historical Period: 2022-2024
• Base Year: 2025
• Forecast Period: 2025-2032
• Units: Value market in US$
• Companies Mentioned: 15

Autoimmune Disease Diagnostics Market by Geographic Region

• North America (The United States, Canada, and Mexico)
• Europe (Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe)
• Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
• South America (Brazil, Argentina, and Rest of South America)
• Rest of World

Autoimmune Disease Diagnostics Market by Product

• Reagents & Consumables
• Instruments

Autoimmune Disease Diagnostics Market by Disease Type

• Systemic Autoimmune Diseases
  • Rheumatoid Arthritis (RA)
  • Multiple Sclerosis (MS)
  • Systemic Lupus Erythematosus (SLE)
  • Psoriasis
  • Other Systemic Autoimmune Diseases (Including Scleroderma, Sjogren's Syndrome, Dermatomyositis, Mixed Connective Tissue Disease, Behcet's Syndrome, Sarcoidosis, Myasthenia Gravis, and others)
• Localized Autoimmune Diseases
  • Type 1 Diabetes
  • Inflammatory Bowel Disease (IBD)
  • Thyroid Disorders
  • Other Localized Autoimmune Diseases (Including Idiopathic Thrombocytopenic Purpura (ITP), Celiac Disease, Addison's Disease, Guillain-Barre Syndrome, Autoimmune Hepatitis, Primary Biliary Cirrhosis, and others)

Autoimmune Disease Diagnostics Market by Test Type

• Antinuclear Antibody (ANA) Tests
• Autoantibodies and Immunologic Tests
• Complete Blood Count (CBC)
• C-reactive Protein (CRP) Test
• Urinalysis
• Other Tests (Including Molecular Diagnostics, Inflammatory Markers, Point-of-care tests, Imaging diagnostics, and Emerging Tests)

This product will be delivered within 2-4 business days.